Sulfateq BV | Empowering health
  • Home
  • About us
  • Programs & Pipeline
  • Scientific data
  • Partnering
    • Investors
  • Newsroom
  • Contact us
Select Page

Empowering health

About Sulfateq B.V.

Sulfateq BV is an innovative privately-held biotechnology company that is developing breakthrough compounds for the treatment of a wide range of therapeutic indications related to mitochondrial dysfunction. Our compound library emerged from research on natures natural mechanisms to cope with mitochondrial stress, including hibernation. SUL compounds have an unique mechanism-of-action and the potential to revolutionize the standard-of-care of diseases associated with a declined mitochondrial function.

Learn more

We strongly believe in the potential of our science to deliver new treatments and improve quality of life for patients with non-communicable diseases involving mitochondrial dysfunction.

Learn More

We are always open for new innovative partnerships. Please contact us to discuss the opportunities. 

Learn More

GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

by Raymond Tel | Jul 28, 2025

View all posts

Sulfateq B.V.



+31 503137464



info@sulfateqbv.com



Admiraal de Ruyterlaan 5, 9726 GN, Groningen

  • RSS
Sulfateq BV - Copyright 2021